Clearly disappointing but...
CEO mentioned that secondary end points are enough for potential approval at premium price point for EU and AU. At these levels, no point selling as one day they will make revenue from bronchitol for bronchictasis.
Long term hold in my SMSF.
- Forums
- ASX - By Stock
- SNT
- ph 3 trial fails primary endpoint
ph 3 trial fails primary endpoint, page-15
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
|
|||||
Last
3.4¢ |
Change
-0.001(2.86%) |
Mkt cap ! $43.87M |
Open | High | Low | Value | Volume |
3.5¢ | 3.5¢ | 3.4¢ | $14.00K | 402.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 440288 | 3.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.6¢ | 374403 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 440288 | 0.034 |
3 | 722272 | 0.033 |
4 | 1156634 | 0.032 |
2 | 1400000 | 0.031 |
5 | 934833 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.036 | 374403 | 3 |
0.037 | 134700 | 2 |
0.038 | 423620 | 3 |
0.039 | 348913 | 2 |
0.040 | 153612 | 3 |
Last trade - 15.50pm 30/08/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online